Pharmaceuticals company Ipca Laboratories announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Standalone Net total Income up 9% at Rs 1,659.93 crore. Consolidated Net total Income up 11% at Rs 2,272.51 crore. Indian formulations income up 11% at Rs 764.05 crore. Exports Income up 6% at Rs 774.29 crore. • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 21.19% in Q4FY25 as against @ 18.50% in Q4FY24. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 18.24 % in Q4FY25 as against @ 14.98 % in Q4FY24. Standalone Net Profit at Rs 216.49 crore (before exceptional items) up 36%. Consolidated Net Profit at Rs 270.83 crore (before exceptional items) up 94%. The Board has recommended a final dividend of Rs 2/- per share (200%). FY25 Financial Highlights: Standalone Net Total Income up 8% at Rs 6,749.21 crore. Consolidated Net Total Income up 15% at Rs 9,032.39 crore. Indian formulations income up 12% at Rs 3,455.10 crore. Exports Income up 4% at Rs 2,808.96 crore. Standalone EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 22.66% in FY25 as against @ 19.29 % in FY24. Consolidated EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 18.94% in FY25 as against @ 16.72% in FY24. Standalone Net Profit at Rs 932.30 crore (before exceptional items) up 40%. Consolidated Net Profit at Rs 992.58 crore (before exceptional items) up 56%. Result PDF